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Research Letters
Transcerebral Exchange Kinetics of Nitrite and Calcitonin
Gene-Related Peptide in Acute Mountain Sickness
Evidence Against Trigeminovascular Activation?
Damian M. Bailey, PhD, FRSC; Sarah Taudorf, MD; Ronan M.G. Berg, MD;
Lars T. Jensen, MD, DMSc; Carsten Lundby, PhD; Kevin A. Evans, MSc; Philip E. James, PhD;
Bente K. Pedersen, MD, DMSc; Kirsten Moller, MD, PhD, DMSc
Background and Purpose—High-altitude headache is the primary symptom associated with acute mountain sickness,
which may be caused by nitric oxide-mediated activation of the trigeminovascular system. Therefore, the present study
examined the effects of inspiratory hypoxia on the transcerebral exchange kinetics of the vasoactive molecules, nitrite
(NO2• ), and calcitonin gene-related peptide (CGRP).
Methods—Ten males were examined in normoxia and after 9-hour exposure to hypoxia (12.9% O2). Global cerebral blood
flow was measured by the Kety-Schmidt technique with paired samples obtained from the radial artery and jugular
venous bulb. Plasma CGRP and NO2• were analyzed via radioimmunoassay and ozone-based chemiluminescence. Net
cerebral exchange was calculated by the Fick principle and acute mountain sickness/headache scores assessed via
clinically validated questionnaires.
Results—Hypoxia increased cerebral blood flow with a corresponding increase in acute mountain sickness and headache
scores (P0.05 vs normoxia). Hypoxia blunted the cerebral uptake of NO2• , whereas CGRP exchange remained
unaltered. No relationships were observed between the change (hypoxia–normoxia) in cerebral NO2• or CGRP exchange
and acute mountain sickness/headache scores (P0.05).
Conclusion—These findings argue against sustained trigeminovascular system activation as a significant event in acute
mountain sickness. (Stroke. 2009;40:2205-2208.)
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High-altitude headache is the most common central ner-vous system complication that occurs in response to the
inspiratory hypoxia of high altitude.1,2 Recent evidence sug-
gests that it is not directly attributable to mild high-altitude
cerebral edema defined by vasogenic edematous brain swell-
ing or intracranial hypertension.3 The prophylactic benefits of
sumatriptan4 suggests that activation of the trigeminal vascu-
lar system may prove an alternative mechanism.
To explore this in more detail, the present study examined
the effects of hypoxia on the cerebral metabolism of nitrite
(NO2• ), an important intravascular reserve of nitric oxide
(NO),5 and calcitonin gene-related peptide (CGRP). These
vasoactive molecules act synergistically to promote neuro-
genic vasodilatation and trigeminal vascular system activa-
tion, which is considered the primary mechanism responsible
for vascular headaches at sea level.6 We hypothesized that if
NO-mediated trigeminal vascular system activation is impli-
cated in the pathophysiology of acute mountain sickness
(AMS), hypoxia would result in a cerebral uptake or con-
sumption of NO2• , thus increasing the bioavailable pool of
NO. We further reasoned that this would stimulate the
synthesis and net cerebral output of CGRP that would be
positively related to corresponding symptom scores.
Materials and Methods
Subjects and Design
Ten healthy males aged 27 (mean)4 (SD) years without any history
of headache, migraine, or AMS provided written informed consent
following approval by the Scientific Ethics Committee of Copenha-
gen and Frederiksberg Municipalities (Denmark). Catheters were
placed under local anesthesia in the radial artery and the right
internal jugular vein via ultrasound guidance with the tip pointing
cranially. After 30 minutes of supine rest, measurements were
obtained in normoxia (21% O2), and measurements were obtained
after 9 hours of passive exposure to normobaric hypoxia (12.9% O2).
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Cerebral Hemodynamics
Hemoglobin (Hb), hematocrit (Hct), partial pressures of oxygen,
carbon dioxide (PO2/PCO2), and oxyhemoglobin saturation (SO2)
were determined using a blood gas analyzer (ABL 715 Radiometer).
Global cerebral blood flow (CBF) was measured using the Kety-
Schmidt technique7 in the desaturation mode using 5% nitrous oxide
as the tracer with a coefficient of variation (CV) of 12%.8 To
normalize for the cerebral vasoconstrictive effects of hypocapnia
during the hypoxic challenge, absolute CBF values were also
adjusted for changes in PaCO2:
Adjusted CBFHYPOXIAmeasured CBFHYPOXIA
[1(PaCO2HYPOXIAPaCO2NORMOXIA)0.03)]
Global cerebral plasma flow (CPF) was calculated as CBF(1Hct),
and cerebral O2 delivery as CBFarterial oxygen content [1.39
(Hb)(SO2/100)(0.003PO2)].
Metabolic Measurements
Blood was centrifuged at 600g (4°C) for 10 minutes and K-EDTA
plasma injected into tri-iodide reagent for the measurement of NO2•
via ozone-based chemiluminescence with an intra and interassay CV
of 7% and 10%, respectively (detection limit 1 nmol/L) based on
data collected in healthy volunteers.9 Plasma CGRP was analyzed
using the most accurate, precise, sensitive, specific, and validated
radioimmunoassay currently available with an intra and interassay
CV of 2% and 7% (detection limit 1 pmol/L) based on healthy
volunteers.10,11 In our experience, these techniques yield normative
(radial) arterial and (jugular) venous concentrations of NO2• and
CGRP that range between 150 and 850 nmol/L and 50 and
100pmol/L at rest in normoxia, which is consistent with the pub-
lished literature.11,12 Cerebral net exchange was calculated as (unad-
justed) CPFarteriovenous concentration difference (a-vdiff).
Cephalalgia
AMS was assessed using the Lake Louise and Environmental
Symptoms Questionnaire Cerebral scoring systems and a visual
analogue scale was used to examine headache as previously
described.13
Statistical Analysis
Shapiro-Wilk W tests confirmed distribution normality. Data were
analyzed with a 2-way repeated measures analysis of variance
(conditionsample site) with post hoc Bonferroni-corrected paired
samples t tests. Relationships were analyzed using a Pearson Product
Moment Correlation. Significance was established at P0.05 and
values are presented as meanSD.
Results
Cerebral Hemodynamics
Hypoxia resulted in marked arterial hypoxemia as reflected
by a reduction (P0.05 vs normoxia) in PaO2, SaO2, and
PaCO2 (Table 1). Global CBF (absolute and PaCO2-adjusted
values) and corresponding CPF tended to increase, thus
preserving cerebral O2 delivery.
Cerebral Metabolic Exchange
Normoxia was associated with a positive a-vdiff and, hence,
net cerebral influx or uptake of NO2• (Figure, A and B),
whereas CGRP exchange was unremarkable (Figure, C and
D). Hypoxia blunted the cerebral uptake of NO2• attributable
primarily to a decrease in arterial delivery, whereas no
changes were observed in systemic or cerebral CGRP
metabolism.
Cephalagia
Hypoxia increased the severity of AMS and corresponding
headache scores (Table 2), although these were unrelated to
any of the changes observed in CBF (r0.26–0.44; P0.05)
or cerebral exchange of NO2 (r0.42–0.14, P0.05) and
CGRP (r0.13–0.08; P0.05).
Discussion
These findings fail to support our original hypothesis and
contrast with some of the observations reported in the
migraine (without aura) literature, a complication of the
central nervous system that shares phenotypic characteristics
that are virtually indistinguishable from those encountered in
AMS. Goadsby et al14 were the first to document increased
CGRP levels in the external jugular venous blood of patients
during migraine attack, a finding that has since been repli-
cated in cubital venous15 and internal jugular venous16 blood.
Furthermore, CGRP infusion causes migraine-like head-
Table 1. Cerebral Hemodynamics
Condition
Sample Site
Normoxia Hypoxia
Arterial Venous Arterial Venous
PO2 (mm Hg) 1076 382* 463† 292*†
Main effects for conditionsample siteinteraction effect
SO2 (%) 991 662 833 515
Main effects for conditionsample site
PCO2 (mm Hg) 432 532* 352† 442*†
Main effects for conditionsample siteinteraction effect
CBF (mL/100g/min) 8515 9417
Adjusted CBF (mL/100g/min) 8515 12324†
CPF (mL/100g/min) 519 5711
Adjusted CPF (mL/100g/min) 519 7416†
O2 delivery (mol/g/min) 7.31.4 8.61.4
CBF/CPF indicates global cerebral blood/plasma flow expressed in absolute values and adjusted for changes in
PaCO2; PO2/PCO2, partial pressure of oxygen/carbon dioxide; SO2, oxyhemoglobin saturation.
*Different vs arterial for given condition (P0.05).
†Different vs normoxia for given sample site (P0.05).
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ache,17 and antagonism with BIBN 4096 BS provides effec-
tive prophylaxis.18
However, these findings have not been consistently repro-
duced caused, in part, by weak experimental design using
historic control subjects and technical deficiencies associated
with the accurate measurement of CGRP. Using an intrapa-
tient comparative design and a more sensitive radioimmuno-
assay, a recent study failed to confirm any difference in CGRP
levels from cubital and external jugular venous blood of patients
during and outside of migraine attack without aura.11
This agrees with our current findings that adopted a similar
experimental approach specifically designed to minimize the
considerable interindividual variation associated with resting
levels of CGRP. Incorporation of a homogenous group of
apparently healthy males in the resting state excluded the
potential confounding influence and interpretive complica-
tions associated with differences in sex, age, arterial hyper-
tension, pregnancy, contraceptive pill use, and exercise on
resting CGRP levels.11 Thus, we remain confident that the
lack of CGRP output across the brain reflects the true
physiological response to hypoxia and is not an artifact
caused by methodological limitations.
However, because the half-life of CGRP has been esti-
mated at only a few minutes,19 we cannot exclude acute
release from trigeminal perivascular nerve fibers, the site of
migraine nociception, during the initial early phase of hyp-
oxia. It is conceivable that the decreased arterial delivery of
NO2• may reflect an increase in the systemic rate of NO2•
reduction by deoxyhemoglobin to increase the intravascu-
lar pool of bioavailable NO5 (Hb-Fe2NO2•H3Hb-
Fe3NOOH). The increase in NO may not only serve
as a countermeasure to effect cerebral vasodilatation to
preserve oxidative metabolism in the face of prevailing
hypoxemia but may have also stimulated focal CGRP syn-
thesis and release resulting in neurogenic vasodilatation,
inflammation, hyperalgesia, and allodynia.20 Alternatively,
the blood–brain barrier, which we have shown to remain
mostly intact during hypoxia,13 may have also prevented
intrathecally formed CGRP from entering the extracranial
circulation in sufficient amounts to permit molecular detection.
However, what is apparent from the current findings is that
the lack of CGRP exchange at 9 hours excludes sustained
steady-state release of CGRP as the primary cause of AMS.
Because accumulating evidence suggests that CGRP is con-
sidered a biological marker of peripheral trigeminal vascular
system activation,6 our findings suggest that alternative
mechanisms are likely responsible for the high-altitude head-
ache observed in AMS.
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Figure. Arterio-jugular venous plasma concentration and cerebral net exchange of NO (A, B) and CGRP (C, D). A positive value for
exchange indicates net influx or uptake across the brain. *Different vs arterial sample site for given condition (P0.05). †Different vs
normoxia for given sample site (P0.05).
Table 2. Cephalalgia
Condition Normoxia Hypoxia
LL (points) 00 32*
ESQ-C (AU) 0.0000.000 0.8030.674*
VAS (mm) 00 2923*
LL indicates Lake Louise; ESQ-C, Environmental Symptoms Questionnaire-
Cerebral Symptoms; VAS, Visual Analogue Scale scores.
*Different vs normoxia (P0.05).
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